Helius Medical Technologies, Inc. (NASDAQ:HSDT – Get Rating) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 173,600 shares, a growth of 192.7% from the July 15th total of 59,300 shares. Based on an average daily trading volume, of 2,350,000 shares, the short-interest ratio is presently 0.1 days.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of HSDT. Altium Capital Management LP bought a new position in shares of Helius Medical Technologies in the fourth quarter worth $254,000. Kepos Capital LP boosted its stake in Helius Medical Technologies by 296.4% in the fourth quarter. Kepos Capital LP now owns 100,304 shares of the company's stock valued at $521,000 after buying an additional 75,000 shares in the last quarter. Finally, AIGH Capital Management LLC acquired a new stake in Helius Medical Technologies in the fourth quarter valued at about $1,298,000. Institutional investors own 29.74% of the company's stock.
Get
Helius Medical Technologies alerts:
Helius Medical Technologies Stock Performance
Shares of NASDAQ HSDT opened at $0.51 on Thursday. Helius Medical Technologies has a 52 week low of $0.45 and a 52 week high of $15.68. The stock has a market capitalization of $1.94 million, a P/E ratio of -0.07 and a beta of 0.72. The stock's fifty day moving average is $1.33 and its 200 day moving average is $2.52.
Helius Medical Technologies (NASDAQ:HSDT – Get Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($1.15) EPS for the quarter. Helius Medical Technologies had a negative return on equity of 240.53% and a negative net
margin of 3,043.95%. The company had revenue of $0.19 million during the quarter. During the same quarter in the prior year, the firm earned ($1.65) EPS. Equities research analysts forecast that Helius Medical Technologies will post -4.18 earnings per share for the current year.
About Helius Medical Technologies
(Get Rating)
Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
Recommended Stories
- Get a free copy of the StockNews.com research report on Helius Medical Technologies (HSDT)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
